We validated the classification ability of these markers in an independent cohort of Danish patients with ALL and found that a subset of these 14 markers (EBF1, VPREB3, LINC00114, ENSG00000227706, CCN2, and NDST3) could perfectly separate B‐ and T‐ALL in this independent cohort (Fig. 8). This evidence concerns the gene CCN2 and acute lymphoblastic leukemia.